From StockTwits: 2025-04-15 14:40:00

Ensysce Biosciences announced positive data from a study showing that their PF614-MPAR pain relief medication effectively treats severe pain while offering protection against overdose. The company completed the first part of a clinical trial confirming the drug’s ability to deliver oxycodone for pain relief and prevent overdoses from excessive doses. CEO Bill Schmidt highlighted the importance of the company’s Multi-Pill Abuse Resistance platform in preventing prescription medication overdoses. Ensysce plans to commercialize PF614-MPAR and discuss the new data with the FDA. The company will continue with parts 2 and 3 of the clinical trial to finalize the drug product for market release. Stocktwits users are bullish on ENSC stock, with one user expressing optimism for a potential rally to $6 from the current $2 levels. The stock is down significantly year-to-date and over the past 12 months.



Read more at StockTwits: Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled